Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

AI-generated analysis

πŸ“‰ Gilead Sciences (GILD) shares fell -8.2% over the past month, underperforming the S&P 500's +12.2% gain and its industry peers' -3% loss.

πŸ’° The company is projected to report quarterly earnings of $1.89 per share for the current quarter, representing a +4.4% increase from the year-ago period.

πŸ“Š Consensus estimates show a +5.8% year-over-year growth trajectory for the current fiscal year based on a consensus EPS of $8.62.

πŸš€ Forward-looking estimates indicate an impressive +11.6% growth for next fiscal year with a projected consensus EPS of $9.62.

πŸ“‰ Recent analyst activity shows slight downward adjustments, with consensus earnings estimates dropping -0.3% over the last 30 days.

🏒 Reported quarterly revenues reached $7.93 billion, exceeding the consensus estimate of $7.57 billion by +4.63%.

πŸ“ˆ The company has a strong track record of beating expectations, surpassing consensus EPS and revenue estimates three times each over the last four quarters.

πŸ’΅ Consensus sales forecasts project current fiscal year revenue of $30.15 billion (+2.4% growth) and next fiscal year at $32.36 billion (+7.4% growth).

βš–οΈ Gilead carries a Zacks Value Style Score of B, indicating the stock is currently trading at a discount relative to its peers.

πŸ›‘οΈ Despite strong fundamental earnings growth projections, the proprietary Zacks Rank tool assigns a rating of #3 (Hold) for near-term performance.

πŸ’‘ The Zacks methodology emphasizes that changes in earnings estimate revisions are a primary driver of fair value and subsequent stock price movements.

πŸ“‰ The company's recent underperformance contrasts with its positive long-term growth metrics and historical ability to beat consensus targets.

πŸ” Analysts note that while fundamental facts drive long-term buy-and-hold decisions, short-term stock direction often follows earnings estimate trends.

Bullish Signals
  • Gilead reported revenues of $7.93 billion in the last quarter, representing a year-over-year growth of +4.7%.
  • The company beat consensus estimates with a revenue surprise of +4.63% and an EPS surprise of +1.64%.
  • Over the last four quarters, Gilead surpassed consensus earnings estimates three times and topped revenue estimates three times.
  • Consensus sales for the current fiscal year are estimated at $30.15 billion with a projected year-over-year increase of +2.4%.
  • The consensus earnings estimate for the next fiscal year is $9.62, indicating an expected growth of +11.6% from the prior year.
  • The Zacks Value Style Score grades Gilead a 'B', indicating the stock is trading at a discount compared to its peers.
Risk Factors
  • Gilead shares have returned -8.2% over the past month, significantly lagging the Zacks S&P 500 composite's +12.2% change and underperforming its own industry which lost only 3%.
  • The Zacks Rank for Gilead is #3 (Hold), suggesting that the stock may perform merely in line with the broader market in the near term rather than outperforming.
  • The consensus earnings estimate has declined (-0.3%) over the last 30 days, while revenue estimates also show a slight downward revision (-0.5%) and minimal adjustment for the next fiscal year (-0.1%).
  • Although the company reported a positive surprise on EPS (+1.64%), the quarterly earnings per share of $1.86 is lower than the prior year's figure of $1.9, indicating underlying earnings pressure.
  • Gilead is graded 'B' on its Zacks Value Style Score, which while indicating a discount to peers, also signals that the stock may not be undervalued enough to justify immediate aggressive buying.
Full Analysis
Gilead Sciences, Inc. (GILD) is currently facing underperformance relative to broader market benchmarks, having declined 8.2% over the past month compared to the S&P 500's gain of 12.2%, while its specific medical and genetic industry sector fell by 3%. The article emphasizes that fundamental earnings projections are more critical for long-term value than short-term rumors or media releases. Analyst consensus estimates indicate a quarterly earnings per share (EPS) of $1.89, representing a 4.4% increase from the previous year, while fiscal year full-year EPS estimates stand at $8.62, up 5.8% year-over-year. Looking further ahead to the next fiscal year, earnings are projected at $9.62, marking an anticipated 11.6% growth rate. Revenue analysis reveals a consensus sales estimate for the current quarter of $6.89 billion, which suggests a 3.4% year-over-year increase, while full-year and next fiscal year sales are estimated at $30.15 billion and $32.36 billion respectively, with projected growth rates of 2.4% and 7.4%. Gilead recently reported actual quarterly revenues of $7.93 billion and EPS of $1.86, both figures exceeding the consensus estimates by 4.63% and 1.64% respectively. Historically, the company has surpassed consensus estimates for earnings three out of four recent quarters and revenue estimates three times over that same period. Valuation analysis utilizing Zacks metrics assigns Gilead a 'B' grade on its Value Style Score, indicating that the stock is currently trading at a discount relative to its peers despite an impressive track record of audited financials. However, the proprietary Zacks Rank tool assigns the company a #3 rating, which suggests a neutral outlook where the stock is expected to perform in line with the broader market rather than significantly outperforming or underperforming. These factors collectively suggest that while earnings growth and recent beat performance are positive, the immediate forward price momentum may remain moderate based on current analyst revisions.